Xconomy -- Coronado Biosciences, a Seattle-based developer of cancer drugs, has raised $7 million in equity and options, according to a filing with the Securities and Exchange Commission. The company lists RJ Tesi as its CEO, and Lindsay Rosenwald, the founder of Paramount Biosciences, as a member of its board.
